CFD-d on keerulised instrumendid, millega kaasneb võimenduse tõttu suur risk kiiresti raha kaotada. 84% jaeinvestoritest kaotab selle pakkuja juures CFD-dega kaubeldes raha. Mõelge järele, kas mõistate CFD-de toimimise põhimõtet ja kas saate endale lubada riski rahast ilma jääda.

Scan to Download iOS&Android APP

Ost-müük CytomX Therapeutics Inc - CTMX CFD

1.86
0%
  • Kokkuvõte
  • Ajaloolised andmed
  • Sündmused
  • Tuluaruanne
  • Bilanss
  • Rahavood
  • Omand
Kauplemistingimused
Hinnavahe 0.05
Pika positsiooni ööpäeva tasu

Long position overnight fee


Margin. Your investment $1,000.00
Üleöö tasu -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Mine platvormile
-0.030779%
Lühikese positsiooni ööpäeva tasu

Short position overnight fee


Margin. Your investment $1,000.00
Üleöö tasu -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Mine platvormile
-0.013666%
Ööpäeva tasu aeg 22:00 (UTC)
Min kauplemise kogus 1
Valuuta USD
Tagatis 20%
Aktsiabörs United States of America
Kauplemise vahendustasu 0%

*Information provided by Capital.com

Võtmestatistika
Eelmine sulgemine* 1.85
Avatud* 1.78
Aastane muutus* -3.78%
Päeva ulatus* 1.78 - 1.95
52 nädala ulatus 1.17-4.73
Keskmine maht (10 päeva) 1.59M
Keskmine maht (3 kuud) 67.17M
Turukapitalisatsioon 181.73M
P/E suhtarv -100.00K
Ringluses olevad aktsiad 66.08M
Tulu 71.94M
EPS -1.49
Dividendid (% kasumist) N/A
Beeta 0.66
Järgmine tuluaruande kuupäev Feb 27, 2023

Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Sulgemishind Change (%) Avamishind High Low
Jun 29, 2022 1.86 0.04 2.20% 1.82 1.96 1.78
Jun 28, 2022 1.85 -0.09 -4.64% 1.94 1.94 1.80
Jun 27, 2022 1.92 0.04 2.13% 1.88 1.97 1.83
Jun 24, 2022 1.87 -0.05 -2.60% 1.92 1.97 1.83
Jun 23, 2022 1.84 0.14 8.24% 1.70 1.85 1.70
Jun 22, 2022 1.77 0.12 7.27% 1.65 1.81 1.62
Jun 21, 2022 1.68 0.06 3.70% 1.62 1.71 1.58
Jun 17, 2022 1.58 -0.03 -1.86% 1.61 1.70 1.57
Jun 16, 2022 1.63 -0.04 -2.40% 1.67 1.67 1.57
Jun 15, 2022 1.70 0.07 4.29% 1.63 1.73 1.61
Jun 14, 2022 1.65 -0.05 -2.94% 1.70 1.72 1.64
Jun 13, 2022 1.71 -0.03 -1.72% 1.74 1.76 1.68
Jun 10, 2022 1.83 -0.02 -1.08% 1.85 1.85 1.77
Jun 9, 2022 1.92 0.07 3.78% 1.85 1.93 1.81
Jun 8, 2022 1.88 0.02 1.08% 1.86 1.98 1.86
Jun 7, 2022 1.86 0.16 9.41% 1.70 1.91 1.67
Jun 6, 2022 1.71 -0.06 -3.39% 1.77 1.83 1.71
Jun 3, 2022 1.76 0.22 14.29% 1.54 1.78 1.54
Jun 2, 2022 1.58 0.06 3.95% 1.52 1.59 1.49
Jun 1, 2022 1.53 -0.05 -3.16% 1.58 1.67 1.50

CytomX Therapeutics Inc Events

Time (UTC) Country Event
No events scheduled
View all events
  • Aastas
  • Kvartalis
2016 2017 2018 2019 2020 2021
Kogutulu 15.043 71.623 59.502 57.489 100.362 69.573
Tulu 15.043 71.623 59.502 57.489 100.362 69.573
Kogu tegevuskulu 74.629 117.882 137.376 168.384 148.967 153.354
Müük/Üldine/admin kulud, kokku 19.874 25.605 33.51 36.765 36.031 39.16
Uuringud ja arendus 54.755 92.277 103.866 131.619 112.936 114.194
Tulud majandustegevusest -59.586 -46.259 -77.874 -110.895 -48.605 -83.781
Intressitulud (kulu), muud tulud, neto 0.736 2.674 7.641 8.365 1.836 0.255
Muud, neto -0.069 -0.027 -0.068 -0.135 -0.027 -0.083
Netotulu enne makse -58.919 -43.612 -70.301 -102.665 -46.796 -83.609
Netotulu pärast makse -58.9 -68.799 -84.604 -102.238 -32.885 -83.609
Netotulu enne erikulusid -58.9 -68.799 -84.604 -102.238 -32.885 -83.609
Netotulu -58.9 -43.099 -84.604 -102.238 -32.885 -83.609
Total Adjustments to Net Income 0 0
Arvestatav tulu, v a erikulud -58.9 -68.799 -84.604 -102.238 -32.885 -83.609
Arvestatav tulu, koos erikuludega -58.9 -43.099 -84.604 -102.238 -32.885 -83.609
Jaotamisele kuuluv netotulu -58.9 -43.099 -84.604 -102.238 -32.885 -83.609
Keskmine jaotamisele kuuluv aktsia kohta 36.2347 37.1668 41.6644 45.3359 46.1456 64.1469
Jaotatav EPS, v a erakorralised kulud -1.62551 -1.85109 -2.03061 -2.25512 -0.71264 -1.3034
Dividends per Share - Common Stock Primary Issue 0 0 0
Jaotamisele kuuluv normaal-EPS -1.62551 -1.85109 -2.03061 -2.25512 -0.71264 -1.3034
Erakorralised kulud kokku 25.7
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Kogutulu 15.971 16.288 17.587 19.727 17.136
Tulu 15.971 16.288 17.587 19.727 17.136
Kogu tegevuskulu 31.598 35.493 40.228 46.035 41.102
Müük/Üldine/admin kulud, kokku 9.227 9.393 11.085 9.456 10.543
Uuringud ja arendus 22.371 26.1 29.143 36.579 30.559
Tulud majandustegevusest -15.627 -19.205 -22.641 -26.308 -23.966
Intressitulud (kulu), muud tulud, neto 0.068 0.044 0.07 0.073 0.068
Muud, neto 0.005 -0.082 -0.013 0.007 0.013
Netotulu enne makse -15.554 -19.243 -22.584 -26.228 -23.885
Netotulu pärast makse -15.554 -19.243 -22.584 -26.228 -23.885
Netotulu enne erikulusid -15.554 -19.243 -22.584 -26.228 -23.885
Netotulu -15.554 -19.243 -22.584 -26.228 -23.885
Arvestatav tulu, v a erikulud -15.554 -19.243 -22.584 -26.228 -23.885
Arvestatav tulu, koos erikuludega -15.554 -19.243 -22.584 -26.228 -23.885
Jaotamisele kuuluv netotulu -15.554 -19.243 -22.584 -26.228 -23.885
Keskmine jaotamisele kuuluv aktsia kohta 60.9681 65.056 65.2081 65.3086 65.3937
Jaotatav EPS, v a erakorralised kulud -0.25512 -0.29579 -0.34634 -0.4016 -0.36525
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Jaotamisele kuuluv normaal-EPS -0.25512 -0.29579 -0.34634 -0.4016 -0.36525
  • Aastas
  • Kvartalis
2016 2017 2018 2019 2020 2021
Käibevarad kokku 188.147 388.601 445.475 303.335 324.013 310.301
Raha ja lühiajalised investeeringud 181.938 374.11 436.127 296.145 316.119 305.226
Raha ja ekvivalendid 104.645 177.548 247.577 188.425 191.859 205.53
Lühiajalised investeeringud 77.293 196.562 188.55 107.72 124.26 99.696
Laekumata arved, neto 2.313 10.139 0.097 0.013 0.798 0.79
Accounts Receivable - Trade, Net 2.313 10.139 0.097 0.013 0.798 0.79
Prepaid Expenses 3.896 4.352 9.251 7.177 7.096 4.285
Total Assets 199.128 397.644 457.108 341.282 358.663 339.411
Property/Plant/Equipment, Total - Net 4.392 4.218 6.934 32.754 29.445 25.322
Property/Plant/Equipment, Total - Gross 8.135 9.426 13.88 41.804 40.871 39.154
Accumulated Depreciation, Total -3.743 -5.208 -6.946 -9.05 -11.426 -13.832
Goodwill, Net 0.949 0.949 0.949 0.949 0.949 0.949
Intangibles, Net 1.75 1.604 1.458 1.312 1.167 1.021
Other Long Term Assets, Total 3.89 2.272 2.292 2.932 3.089 1.818
Total Current Liabilities 35.767 61.147 97.908 85.59 100.924 106.316
Accounts Payable 6.596 4.205 5.132 4.158 2.996 2.818
Accrued Expenses 8.824 16.383 26.724 30.051 23.059 34.236
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 20.347 40.559 66.052 51.381 74.869 69.262
Total Liabilities 120.649 327.748 326.225 290.169 308.86 250.032
Total Long Term Debt 0 0 0 0 0 0
Deferred Income Tax 0.513
Other Liabilities, Total 84.369 266.601 228.317 204.579 207.936 143.716
Total Equity 78.479 69.896 130.883 51.113 49.803 89.379
Common Stock 0.001 0.001 0.001 0.001 0.001 0.001
Additional Paid-In Capital 254.871 289.454 445.956 468.285 499.964 623.344
Retained Earnings (Accumulated Deficit) -176.366 -219.465 -314.981 -417.23 -450.115 -533.724
Other Equity, Total -0.027 -0.094 -0.093 0.057 -0.047 -0.242
Total Liabilities & Shareholders’ Equity 199.128 397.644 457.108 341.282 358.663 339.411
Total Common Shares Outstanding 36.4902 38.4786 45.0832 45.5231 48.2518 65.3928
Preferred Stock - Non Redeemable, Net 0 0 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Käibevarad kokku 400.008 271.005 240.998 310.301 268.444
Raha ja lühiajalised investeeringud 393.796 266.177 236.289 305.226 262.53
Raha ja ekvivalendid 329.666 256.146 236.284 205.53 163.488
Lühiajalised investeeringud 64.13 10.031 0.005 99.696 99.042
Laekumata arved, neto 0.756 0.931 0.887 0.79 1.016
Accounts Receivable - Trade, Net 0.756 0.931 0.887 0.79 1.016
Prepaid Expenses 5.456 3.897 3.822 4.285 4.898
Total Assets 434.158 402.44 371.233 339.411 296.825
Property/Plant/Equipment, Total - Net 28.908 27.66 26.441 25.322 24.629
Goodwill, Net 0.949 0.949 0.949 0.949 0.949
Intangibles, Net 1.13 1.094 1.057 1.021 0.984
Other Long Term Assets, Total 3.163 1.818 1.819 1.818 1.819
Total Current Liabilities 98.049 93.377 99.772 106.316 102.766
Accounts Payable 2.582 1.755 1.516 2.818 1.721
Accrued Expenses 18.831 19.253 25.167 34.236 31.032
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 76.636 72.369 73.089 69.262 70.013
Total Liabilities 288.136 271.487 259.559 250.032 228.631
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 190.087 178.11 159.787 143.716 125.865
Total Equity 146.022 130.953 111.674 89.379 68.194
Preferred Stock - Non Redeemable, Net 0 0
Common Stock 0.001 0.001 0.001 0.001 0.001
Additional Paid-In Capital 611.733 615.849 619.117 623.344 626.721
Retained Earnings (Accumulated Deficit) -465.669 -484.912 -507.496 -533.724 -557.609
Other Equity, Total -0.043 0.015 0.052 -0.242 -0.919
Total Liabilities & Shareholders’ Equity 434.158 402.44 371.233 339.411 296.825
Total Common Shares Outstanding 65.0029 65.157 65.2491 65.3928 65.3984
Long Term Investments 99.914 99.969
  • Aastas
  • Kvartalis
2016 2017 2018 2019 2020 2021
Netotulu/algväärtus -58.9 -43.099 -84.604 -102.238 -32.885 -83.609
Raha majandustegevusest -2.032 170.373 -75.521 -140.48 5.259 -119.031
Raha majandustegevusest 1.733 1.645 1.884 2.459 2.427 2.56
Deferred Taxes 0.006 -0.513
Mittelikviidsed varad 11.869 22.375 15.177 18.474 17.437 16.572
Muutused tööjõus 43.26 189.965 -7.978 -59.321 18.134 -54.7
Tulu investeeringutelt 45.859 -121.266 5.926 79.701 -18.718 22.489
Kapitalikulutused -2.176 -1.559 -3.788 -3.497 -2.309 -1.609
Muud rahavood investeeringutelt, kokku 48.035 -119.707 9.714 83.198 -16.409 24.098
Rahavood investeeringutelt 0.996 23.796 139.624 1.627 16.893 110.213
Rahavoogudesse investeerimine -0.012 0 0
Aktsiate emiteerimine (tagasiost), neto 0.93 23.796 139.624 1.627 16.893 110.213
Laenu väljastamine (kustutamine), neto 0.078 0
Rahaline kogumuutus 44.823 72.903 70.029 -59.152 3.434 13.671
Amortization 0.146 0.146 0.146
Cash Taxes Paid 13.061 0 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -15.554 -34.797 -57.381 -83.609 -23.885
Cash From Operating Activities -29.94 -58.139 -87.839 -119.031 -41.313
Cash From Operating Activities 0.638 1.278 1.921 2.56 0.565
Amortization 0.036 0.073 0.11 0.146 0.037
Non-Cash Items 3.934 8.274 12.235 16.572 4.179
Changes in Working Capital -18.994 -32.967 -44.724 -54.7 -22.209
Cash From Investing Activities 59.012 13 22.734 22.489 -0.736
Capital Expenditures -0.982 -1.096 -1.364 -1.609 -0.736
Other Investing Cash Flow Items, Total 59.994 14.096 24.098 24.098 0
Cash From Financing Activities 108.735 109.426 109.53 110.213 0.007
Issuance (Retirement) of Stock, Net 108.735 109.426 109.53 110.213 0.007
Net Change in Cash 137.807 64.287 44.425 13.671 -42.042
Investori nimi Investori liik Ringluse protsent Hoitud osakud Muutus osakutes Hoidmise kuupäev Hinnang käibele
BVF Partners L.P. Hedge Fund 9.9809 6595801 0 2022-09-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 6.8669 4537961 -540426 2022-09-30 LOW
Tang Capital Management, LLC Hedge Fund 5.2963 3500000 29100 2022-09-30 MED
Acadian Asset Management LLC Investment Advisor/Hedge Fund 4.0154 2653576 814350 2022-09-30 MED
Rubric Capital Management LP Hedge Fund 3.6415 2406449 0 2022-09-30 MED
Renaissance Technologies LLC Hedge Fund 2.7323 1805600 351339 2022-09-30 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 2.6528 1753118 -24021 2022-09-30 LOW
Medical Strategy GmbH Investment Advisor 2.5583 1690646 0 2022-09-30 LOW
Laurion Capital Management LP Hedge Fund 1.9231 1270900 0 2022-09-30 HIGH
Platinum Asset Management Investment Advisor/Hedge Fund 1.8606 1229545 0 2022-09-30 LOW
Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 1.7085 1129058 191388 2022-09-30 MED
Assenagon Asset Management S.A. Investment Advisor 1.3844 914900 -150492 2022-12-31 HIGH
Two Sigma Investments, LP Hedge Fund 1.3397 885361 200477 2022-09-30 HIGH
Newtyn Management, LLC Hedge Fund 1.2106 800000 -273400 2022-09-30 MED
Fidelity Management & Research Company LLC Investment Advisor 1.0354 684209 -1637 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.8889 587451 4386 2022-09-30 LOW
Oasis Management Company Ltd. Investment Advisor 0.818 540541 0 2022-09-30 MED
Millennium Management LLC Hedge Fund 0.8058 532513 -909219 2022-09-30 HIGH
Gluck (Frederick W) Individual Investor 0.8021 530069 0 2022-04-18 LOW
D. E. Shaw & Co., L.P. Hedge Fund 0.7409 489630 242153 2022-09-30 HIGH

Miks valida Capital.com? Meie numbrid räägivad iseenda eest.

Capital.com Group
+500000+

Kauplejad

93000+

Igakuiste aktiivsete klientide arv

$57000000+

Igakuine investeerimise maht

$31000000+

Igakuiselt välja võetud

Kauplemiskalkulaator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Kauplemise vahendustasu
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Finantsvõimendus
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind

Close

Lühike Pikk

CytomX Therapeutics Inc Company profile

Ettevõttest CytomX Therapeutics Inc

CytomX Therapeutics, Inc. on kliinilises staadiumis, onkoloogiale keskendunud biofarmatseutiline ettevõte. Ettevõte arendab oma Probody tehnoloogiaplatvormil põhinevaid uuritavaid tingimuslikult aktiveeritud ravimeid vähktõve raviks. Probody tehnoloogiaplatvormi eesmärk on võimaldada antikehapõhiste ravimite tingimuslikku aktiveerimist kasvaja mikrokeskkonnas, vähendades samal ajal ravimi aktiivsust tervetes kudedes ja ringluses. Ettevõtte tootekandidaatide hulka kuuluvad tingimuslikult aktiveeritud antikeha-ravimikonjugaadid (ADC) praluzatamab ravtansine (CX2009, suunatud CD166 vastu) ja CX-2029, suunatud CD71 vastu, ning Probody immuunsüsteemi kontrollpunkti inhibiitorid pacmilimab (CX-072, suunatud PD-L1 vastu) ja BMS-986249 (suunatud CTLA-4 vastu). Samuti on kaks prekliinilist ainet uue ravimi (IND) uuringutes - tingimuslikult aktiveeritud ADC, mis on suunatud EpCAM/Trop-1-le (CX-2043), ja tingimuslikult aktiveeritud T-rakkudega seotud bispetsiifiline antikeha, mis on suunatud EGFR-le ja CD3-le (CX-904).

Industry: Bio Therapeutic Drugs

650 Gateway Blvd.
Suite 125
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Tuluaruanne

  • Annual
  • Quarterly

Teised on vaadanud veel

BTC/USD

22,779.20 Price
-1.510% 1D Chg, %
Pika positsiooni ööpäeva tasu -0.0500%
Lühikese positsiooni ööpäeva tasu 0.0140%
Ööpäeva tasu aeg 22:00 (UTC)
Hinnavahe 60.00

Oil - Crude

78.36 Price
-0.430% 1D Chg, %
Pika positsiooni ööpäeva tasu -0.0163%
Lühikese positsiooni ööpäeva tasu 0.0021%
Ööpäeva tasu aeg 22:00 (UTC)
Hinnavahe 0.03

US100

12,643.60 Price
+1.040% 1D Chg, %
Pika positsiooni ööpäeva tasu -0.0190%
Lühikese positsiooni ööpäeva tasu 0.0076%
Ööpäeva tasu aeg 22:00 (UTC)
Hinnavahe 1.8

XRP/USD

0.40 Price
-1.180% 1D Chg, %
Pika positsiooni ööpäeva tasu -0.0500%
Lühikese positsiooni ööpäeva tasu 0.0140%
Ööpäeva tasu aeg 22:00 (UTC)
Hinnavahe 0.00351

Kas otsite jätkuvalt vahendajat, keda saab usaldada?

Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com

1. Looge ja kinnitage oma konto 2. Tee sissemakse 3. Alusta kauplemist